<DOC>
	<DOC>NCT00638872</DOC>
	<brief_summary>The main objective of the study is to evaluate the efficacy of the polydeoxyribonucleotide in improving the healing of diabetic foot ulcers.</brief_summary>
	<brief_title>Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers</brief_title>
	<detailed_description>This trial will involve diabetic patients with foot ulcers who meet the inclusion/exclusion criteria. At least 200 patients aged 45-80yrs will be enrolled in the study and randomly allocated to receive the active drug or the placebo in indistinguishable formulations. After 2 months closure rate of the ulcer will be evaluated.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Male or female aged 4580yrs Minimum schooling 5yrs Type I or II diabetes since at least 5yrs with a stable metabolic control Foot ulcer since minimum 2 weeks Ulcer &gt;1cm and &lt;16cm at day 0 Ulcer grade 1 or 2 wagner scale Wound free of necrotic debris TcPO2 &gt;29mmHg Not pregnant or lactant Nonconsenting patient History of alcohol or drug abuse Gangrene on any part of the affected foot Ongoing untreated infections Ulcer over a charcot deformity Use of a systemic cicatrizant drug in the past 10 days Malnutrition Neurological or psychiatric pathologies Liver or kidney insufficiency Corticosteroid or immunosuppressive or cytotoxic therapy Other severe pathologies Proven hypersensitivity to the drug or to any related component</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>diabetes</keyword>
	<keyword>foot ulcer</keyword>
	<keyword>polydeoxyribonucleotide</keyword>
</DOC>